CAS No. |
1374248-77-7 |
中文名称 |
(S)-N-((3S,5S,6R)-6-甲基-2-氧代-5-苯基-1-(2,2,2-三氟乙基)哌啶-3-基)-2'-氧代-1',2',5,7-四氢螺[环戊并[b]吡啶-6,3'-吡咯并[2,3-b]吡啶]-3-甲酰胺 |
英文名称 |
(S)-N-((3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide |
别名 |
Ubrelvy (TN) | UNII-AD0O8X2QJR | SY001508 | A934103 | D10673 | Ubrogepant (USAN/INN) | Ubrogepant [USAN] | AKOS040742798 | DB15328 | AC-31965 | MS-30058 | UBROGEPANT [MI] | Q15632908 | BDBM361594 | Ubrogepantum | (6S)-N-[(3S,5S,6R)-6-Methyl-2-oxo-5-phenyl |
标准英文名 |
(S)-N-((3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide |
MDL No. |
MFCD28386182 |
分子式 |
C29H26F3N5O3 |
分子量 |
549.20
|
精确分子量 |
549.20
|
SMILES |
O=C1[C@]2(CC3=CC(C(N[C@H]4C[C@@H](C5=CC=CC=C5)[C@H](N(C4=O)CC(F)(F)F)C)=O)=CN=C3C2)C6=CC=CN=C6N1 |
标准SMILES |
C[C@@H]1[C@@H](C[C@H](NC(=O)C2C=C3C[C@]4(CC3=NC=2)C2=CC=CN=C2NC4=O)C(=O)N1CC(F)(F)F)C1C=CC=CC=1 |
用途 |
Ubrogepant is an orally administered small-molecule drug approved by the U.S. Food and Drug Administration (USFDA) for the acute treatment of migraine in adults, with or without aura; it acts as a calcitonin gene-related peptide (CGRP) receptor antagonist and has potential for research related to acute migraine therapy. |
InChIKey |
DDOOFTLHJSMHLN-ZQHRPCGSSA-N |